share_log

Third Largest Player In Baby Formula Jumps In To Ease Shortage In US

Third Largest Player In Baby Formula Jumps In To Ease Shortage In US

婴儿配方奶粉第三大厂商加入缓解美国奶粉短缺
Benzinga Real-time News ·  2022/05/18 16:03
  • Europe's Nestlé SA (OTC:NSRGF) is ramping up hypoallergenic (HA) baby formula production to alleviate the shortage in U.S. supermarkets.
  • In a statement sent to Fortune, Nestlé said it "significantly increased" Gerber Good Start Extensive HA production from the Netherlands and Alfamino from Switzerland, both used to treat babies that respond allergically to sugars like lactose.
  • Nestlé declined to be more specific on the size of increased shipments.
  • A recall by Abbott Laboratories (NYSE:ABT), persistent supply-chain issues, and a highly concentrated market combined to form what one consumer goods expert calls a "perfect storm."
  • Related: US Lawmakers Reveal FDA Emergency Funds Bill To Tackle Baby Formula Shortage: Reuters.
  • The most recent statistics suggest Abbott had a 43% market share, while Mead Johnson, maker of Enfamil, controlled another 40%. By comparison, Nestlé was a distant third with just 15%. 
  • The move comes after the FDA said it was encouraging overseas manufacturers to apply to ship their formula to the U.S., easing rules that had effectively prevented shipments from many such companies.
  • Abbott on Monday said it had reached an agreement with the FDA for the reopening of the Sturgis plant.
  • Photo by Company
  • 欧洲的雀巢公司美国场外交易市场代码：NSRGF)正在增加低过敏性(HA)婴儿配方奶粉的生产，以缓解美国超市的短缺。
  • 在发送到的声明中财运雀巢表示，它“显著增加了”来自荷兰的Gerber Good Start广泛生产的HA和来自瑞士的Alafino，这两种产品都用于治疗对乳糖等糖过敏的婴儿。
  • 雀巢拒绝透露增加出货量的更多细节。
  • 召回雅培(纽约证券交易所股票代码：ABT)、持续的供应链问题和高度集中的市场结合在一起，形成了一位消费品专家所说的“完美风暴”。
  • 相关： 美国国会议员公布FDA紧急资金法案以解决婴儿配方奶粉短缺问题：路透社.
  • 最新的统计数据显示，雅培拥有43%的市场份额，而安非他明的制造商美赞臣则控制着另外40%的市场份额。相比之下，雀巢仅占15%，远远落后于第三名。
  • 在此之前，FDA表示正在鼓励海外制造商申请将其配方奶粉运往美国，放松了实际上阻止许多此类公司发货的规定。
  • 雅培周一表示，已与FDA就斯特吉斯工厂的重新开放达成协议。
  • 照片由公司提供
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发